Epilepsy Studies

If you think you may qualify for one of these studies, please contact CNI’s Research Department at 303-806-7423.

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of brivaracetam in subjects (≥16 to 80 years old) with partial onset seizures: To evaluate the efficacy of BRV compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant AEDs.
eligibility and information
Principal Investigator: Charles Livsey, MD, PhD
Sub-Investigator: Kristen Bracht, MD

A multicenter, double-blind, double-dummy, randomized, positive-controlled study comparing the efficacy and safety of lacosamide (200 to 600mg/day) to controlled release carbamazepine (400 to 1200mg/day), used as monotherapy in subjects (≥16 years) newly or recently diagnosed with epilepsy and experiencing partial-onset or generalized tonic-clonic seizures: To compare the efficacy and safety of LCM to CBZ-CR used as monotherapy for at least 1 year, efficacy being measured as a primary endpoint by 6-month seizure freedom, in newly or recently diagnosed epilepsy subjects.
eligibility and information
Principal Investigator: Charles Livsey, MD, PhD
Sub-Investigator: Kristen Bracht, MD

Neural correlates of cognition in the cortex: An exploration of how behavior and cognition are related to natural electrical signals recorded from the surface of the brain in patients receiving the surgical treatment of epilepsy.
Principal Investigator: Adam Hebb, MD

 

Colorado Neurological Insitute